BioNTech SE (BNTX) is a German biotechnology company that operates globally, focusing on advancements in patient-specific immunotherapies for cancer and other severe diseases. Founded in 2008 by a team of international scientists and physicians comprising of Ugur Sahin, Özlem Türeci and Christoph Huber, it has its headquarters in Mainz, Germany. The company's shares are listed on the NASDAQ stock exchange under the ticker BNTX.
BioNTech's strategic vision is to harness the power of the body's immune system against cancer using targeted mRNA vaccines, innovative chimeric antigen receptor (CAR) T-cell therapies, individualized neoepitope vaccines and adoptive T cell therapies. Their robust pipeline covers a broad range of cancers and infectious diseases, with therapies undergoing evaluation in more than 20 clinical trials worldwide.
BioNTech gained international prominence in 2020 as it rapidly developed and received approval for the first COVID-19 vaccine together with its US partner, Pfizer. The mRNA-based COVID-19 vaccine, BNT162b2, also known as Comirnaty, or colloquially as the Pfizer-BioNTech vaccine, has been pivotal in global COVID-19 vaccination campaigns.
Just as with its cancer-focused immunotherapies, BioNTech’s COVID-19 vaccine uses messenger RNA - a molecule that carries instructions from DNA to the cell's protein-making machinery. This cutting-edge vaccine works by telling our cells to produce a protein that triggers an immune response to the SARS-CoV-2 virus, providing immunity against COVID-19.
Beyond its significant advances in mRNA technology, BioNTech is also a major player in fields such as antibody therapies, cell therapies, and protein therapeutics. With these collective endeavors, BioNTech stands at the forefront of a new age in medicine: a world where diseases are treated by activating the body's internal defenses, promising an era of personalized medicine tailored to the individual.
As of today, BioNTech SE is committed not only to fight against the ongoing pandemic but also to develop other innovative treatments for cancer and infectious diseases, leveraging the power of the body's immune system. The company invests heavily in research and development to maintain its leading position in the biotechnology sphere.
BioNTech's innovative approaches, proven expertise, and commitment to groundbreaking scientific research underscore its place in medical history; certainly, it is a company that has firmly positioned itself at the technology vanguard of global health challenges.